Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 2 Date: 13 Sep 2024
Reviewer:  Kazuo Kobayashi
Reviewer's report:
The manuscript, "Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal
Junction Cancer: A Meta-Analysis of Randomized Controlled Trials," has been revised
thoroughly in response to the reviewer’s comments. The authors have addressed all concerns
appropriately and made significant improvements to the manuscript.
Reviewer Comments Addressed
Clarification of Methodology: The authors have adequately clarified the methodology,
especially regarding the inclusion and exclusion criteria and the rationale behind the study
selection, making the study more transparent.
Improved Discussion: The discussion has been expanded to address specific clinical
recommendations, especially regarding the use of Nivolumab monotherapy versus combination
therapy, as well as the management of adverse events. This has enhanced the clinical relevance
of the findings.
Reduction of Redundancy: The authors have made adjustments to avoid redundancy in the data
analysis by excluding overlapping studies, which strengthens the validity of the meta-analysis.
Overall, the authors have made substantial improvements to the manuscript, and it is now ready
for acceptance.
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 2 Date: 13 Sep 2024
Reviewer:  Kazuo Kobayashi
Reviewer's report:
The manuscript, "Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal
Junction Cancer: A Meta-Analysis of Randomized Controlled Trials," has been revised
thoroughly in response to the reviewer’s comments. The authors have addressed all concerns
appropriately and made significant improvements to the manuscript.
Reviewer Comments Addressed
Clarification of Methodology: The authors have adequately clarified the methodology,
especially regarding the inclusion and exclusion criteria and the rationale behind the study
selection, making the study more transparent.
Improved Discussion: The discussion has been expanded to address specific clinical
recommendations, especially regarding the use of Nivolumab monotherapy versus combination
therapy, as well as the management of adverse events. This has enhanced the clinical relevance
of the findings.
Reduction of Redundancy: The authors have made adjustments to avoid redundancy in the data
analysis by excluding overlapping studies, which strengthens the validity of the meta-analysis.
Overall, the authors have made substantial improvements to the manuscript, and it is now ready
for acceptance.
Please review this paper.
user
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 2 Date: 13 Sep 2024
Reviewer:  Kazuo Kobayashi
Reviewer's report:
The manuscript, "Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal
Junction Cancer: A Meta-Analysis of Randomized Controlled Trials," has been revised
thoroughly in response to the reviewer’s comments. The authors have addressed all concerns
appropriately and made significant improvements to the manuscript.
Reviewer Comments Addressed
Clarification of Methodology: The authors have adequately clarified the methodology,
especially regarding the inclusion and exclusion criteria and the rationale behind the study
selection, making the study more transparent.
Improved Discussion: The discussion has been expanded to address specific clinical
recommendations, especially regarding the use of Nivolumab monotherapy versus combination
therapy, as well as the management of adverse events. This has enhanced the clinical relevance
of the findings.
Reduction of Redundancy: The authors have made adjustments to avoid redundancy in the data
analysis by excluding overlapping studies, which strengthens the validity of the meta-analysis.
Overall, the authors have made substantial improvements to the manuscript, and it is now ready
for acceptance.
assistant